TipRanks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market
IKT
Inhibikase Therapeutics
RESEARCH TOOLSreports
Want to see IKT full AI Analyst Report?

Inhibikase Therapeutics (IKT) Income Statement

380 Followers

Inhibikase Therapeutics Income Statement

Last quarter (Q2 2026), Inhibikase Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Inhibikase Therapeutics's net income was $-19.59M. See Inhibikase Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Mar 23Mar 22
Total Revenue
$ 0.00$ 0.00$ 260.50K$ 123.44K$ 3.10M
Gross Profit
$ 0.00$ -26.27K$ -13.36M$ 116.72K$ -8.26M
Operating Expenses
$ 51.97M$ 28.56M$ 6.73M$ 18.25M$ 6.51M
Depreciation and Amortization
$ 60.50K$ 26.27K$ 177.40K$ 6.72K$ 14.77M
EBITDA
$ -53.29M$ -27.49M$ -18.85M$ -18.05M$ 0.00
Operating Income
$ -51.97M$ -28.59M$ -20.09M$ -18.13M$ -14.77M
Other Income/Expenses
$ 3.72M$ 1.07M$ 1.06M$ 74.45K$ -19.92K
Pretax Income
$ -48.26M$ -27.52M$ -19.03M$ -18.05M$ -14.79M
Net Income
$ -48.26M$ -27.52M$ -19.03M$ -18.05M$ -14.79M
Per Share Metrics
Basic EPS
$ -0.49$ -1.16$ -3.57$ -4.26$ -4.88
Diluted EPS
$ -0.49$ -1.16$ -3.57$ -4.26$ -4.88
Weighted Average Shares Outstanding
 98.31M 23.71M 5.33M 4.20M 3.03M
Weighted Average Shares Outstanding (Diluted)
 98.31M 23.71M 5.33M 4.20M 3.03M
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History